Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

Also called NCT01915459

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Hugel (from the registry)
Registry
  • NCT NCT01915459
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01915459. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
Condition
Stroke
Condition
Spasticity
Intervention (Biological)
Botulinum toxin type A(Botulax®)
Intervention (Biological)
Botulinum toxin type A(Botox®)
Lead sponsor
Hugel (class: industry)

Record details

Record id
cardio:ct-nct01915459
Content hash
3558bebfba5a59518b4faa1ef62e45c40208ae97d1a5cdb77645e0411c606dbe